Tenaya Therapeutics Inc Stock

$0.48

2.25% yesterday

Nasdaq, May 20, 09:50 pm CET

ISIN

US87990A1060

Symbol

TNYA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Tenaya Therapeutics Inc Stock price

$0.48

-14.87 96.90% 5Y

Nasdaq, Closing price Tue, May 20 2025

-0.01 2.44%

ISIN

US87990A1060

Symbol

TNYA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$77.45m
Enterprise Value	$2.20m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	0.65
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-109.72m
Free Cash Flow (TTM) Free Cash Flow	$-85.80m
Cash position	$88.16m
EPS (TTM) EPS	$-1.16
P/E forward	negative
Short interest	14.79%

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Get Started for Free Today

Tenaya Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a Tenaya Therapeutics Inc forecast:

9x Buy

100%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a Tenaya Therapeutics Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Tenaya Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	8.97 8.97	19% 19% -
Gross Profit	-8.97 -8.97	19% 19% -
- Selling and Administrative Expenses	9.01 9.01	22% 22% -
- Research and Development Expense	83 83	15% 15% -
EBITDA	-101 -101	16% 16% -
- Depreciation and Amortization	8.97 8.97	19% 19% -
EBIT (Operating Income) EBIT	-110 -110	16% 16% -
Net Profit	-106 -106	15% 15% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Tenaya Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

5 days ago

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase an aggregate of 461,000 shares of Tenaya common stock to three ne...

Neutral

GlobeNewsWire

●

8 days ago

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of Heart Disease Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of Heart Disease

Neutral

GlobeNewsWire

●

26 days ago

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

RIDGE is Largest Natural History Study Conducted with More Than 175 Participants Enrolled to Date with Arrhythmogenic Right Ventricular Cardiomyopathy Due to Mutations in the PKP2 Gene

More Tenaya Therapeutics Inc News

Company Profile

Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. It operates through its product platforms: gene therapy, cellular regeneration, and precision medicine. The company was founded by Deepak Srivastava, Benoit G. Bruneau, Bruce R. Conklin, Sheng Ding, Saptarsi Haldar, and Eric Olson in 2016 and is headquartered in South San Francisco, CA.

Head office	United States
CEO	Faraz Ali
Employees	97
Founded	2016
Website	www.tenayatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now